FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trialVolker Heinemann, Sebastian Stintzing, Christian Lerchenmüller et al.|The Lancet Oncology|2014Cited by 1.7k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic LeukemiaFrancesco Lo‐Coco, Uwe Platzbecker, Giuseppe Avvisati et al.|New England Journal of Medicine|2013Cited by 1.6k
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trialRalf‐Dieter Hofheinz, Andreas Hochhaus, Frederik Wenz et al.|The Lancet Oncology|2012Cited by 505
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinantsRoland J. Fuchs, Rüdiger Hehlmann, Michael Lauseker et al.|Leukemia|2017Cited by 339